Association of TaqI B polymorphisms of CETP gene and Rosuvastatin with the curative effect of CHD patients with IGT
10.3969/j.issn.1006-5725.2016.20.037
- VernacularTitle:CETP基因TaqI B多态性与瑞苏伐他汀对糖耐量异常合并冠心病患者疗效的相关性
- Author:
Xili YANG
;
Zhaoyan XU
;
Jianyu ZHANG
;
Zhaolun ZHOU
;
Jianmin LI
;
Weibiao CAI
;
Jian LI
;
Jinming CEN
- Publication Type:Journal Article
- Keywords:
Cholesteryl ester transfer protein;
Rosuvastatin;
Gene polymorphism;
Intravascular ultrasound;
Impaired glucose tolerance
- From:
The Journal of Practical Medicine
2016;32(20):3416-3418
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the changes of plasma lipid indexes and coronary artery atherosclerotic plaque in TaqI B genotypes in CHD patients with impaired glucose tolerance (IGT) before and after statin therapy. Methods A total of 196 CHD with IGT and 160 controls were included. The changes of plasma lipid indexes and coronary artery atherosclerotic plaque in TaqI B genotypes were analyzed before and after Rosovastatin therapy. Sequenom Mass ARRAY platform was used to detect the CETP TaqI B SNPs. Results The genotype frequency of the B1B1, B1B2 and B2B2 in CHD with IGT group was 35.7%, 48.0% and 16.3% respectively, while in control group was 31.3%, 53.1% and 15.6% respectively. HDL-C, PA and MLA levels increased after Rosuvastatin therapy, while LDL-C, TG, TCH, Lpa, PA, EEMA and PB levels decreased. Conclusions CETP gene polymorphisms TaqI B would have association with the effects of Rosuvastatin therapy in the CHD with IGT.
